Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OH › Waverly › NPI 1720018971
Physician

Pike Health Services, INC

Pike Health Services, INC was paid $9.12M by Medicaid between Jan 2018 and Dec 2024, across 182 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.

33Billing provider infoPIKE HEALTH SERVICES, INC
WAVERLY, OH 45690
33aNPI1720018971assigned 07/04/2006
33bProvider typeFamily Medicine Physician
28Total paid$9.12M
24GClaims286,353
24DCodes billed182
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Family Medicine Physician providers in Ohio

Rank by total paid#13 of 739
Median peer was paid$30K
This provider vs. median307×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201830,205$729K
201927,911$692K
202025,628$758K
202129,077$999K
202234,568$1.11M
202384,248$2.17M
2024incomplete54,716$2.66M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 22% 18,394 17,152 $2.04M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 11% 8,728 7,548 $983K
99282 Emergency department visit for the evaluation and management, low to moderate severity 7.6% 6,279 5,691 $695K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 7.1% 8,796 6,759 $648K
74176 Computed tomography, abdomen and pelvis; without contrast material 6.4% 2,470 2,015 $579K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 5.8% 5,236 3,863 $527K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5.2% 7,723 6,543 $477K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 4.7% 5,048 4,632 $430K
70450 Computed tomography, head or brain; without contrast material 4.0% 1,866 1,451 $369K
99281 Emergency department visit for the evaluation and management, self-limited or minor 3.2% 2,417 2,193 $293K
97530 Therapeutic activities, direct patient contact, each 15 minutes 2.6% 2,783 789 $236K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder 1.7% 1,919 639 $153K
170 more codes
74177 Computed tomography, abdomen and pelvis; with contrast material 1.5% 549 $137K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.4% 1,404 $128K
96361 Intravenous infusion, hydration; each additional hour 1.1% 446 $104K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour 1.0% 521 $93K
G0378 Hospital observation service, per hour <1% 3,093 $87K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,163 $82K
80048 Basic metabolic panel (calcium, ionized) <1% 12,609 $67K
99213 Doctor's office visit, returning patient (routine) <1% 1,137 $58K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 256 $54K
80053 Comprehensive metabolic panel <1% 9,318 $52K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 252 $50K
71275 Computed tomographic angiography, chest, with contrast material <1% 251 $49K
20611 <1% 131 $37K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 582 $37K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 1,356 $37K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 355 $37K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,517 $37K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 132 $35K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 22,400 $35K
71250 <1% 463 $35K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,417 $31K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 8,728 $24K
84484 <1% 7,619 $20K
36415 Collection of venous blood by venipuncture <1% 27,690 $20K
71045 Radiologic examination, chest; single view <1% 7,725 $20K
71046 Radiologic examination, chest; 2 views <1% 705 $17K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 4,014 $15K
84443 Thyroid stimulating hormone (TSH) <1% 1,739 $14K
80061 Lipid panel <1% 1,842 $14K
94060 <1% 102 $13K
Q3014 Telehealth originating site facility fee <1% 1,144 $11K
83036 Hemoglobin; glycosylated (A1C) <1% 2,478 $11K
73630 <1% 434 $10K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 643 $10K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 141 $10K
72125 Computed tomography, cervical spine; without contrast material <1% 234 $8K
90686 <1% 764 $7K
64493 <1% 14 $7K
J3490 Unclassified drugs <1% 1,065 $6K
80076 <1% 1,986 $6K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 1,634 $6K
62323 <1% 12 $6K
73562 <1% 109 $6K
73610 <1% 272 $5K
83880 <1% 2,136 $5K
81001 <1% 7,775 $5K
72020 <1% 705 $5K
73130 <1% 282 $4K
85610 <1% 4,778 $4K
82607 <1% 380 $4K
73030 <1% 202 $4K
87088 <1% 2,319 $4K
83605 <1% 3,379 $4K
87040 <1% 2,728 $4K
72100 <1% 141 $4K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 865 $4K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 4,095 $4K
70551 Magnetic resonance imaging, brain; without contrast material <1% 15 $3K
83735 <1% 2,795 $3K
85027 <1% 877 $3K
J7030 Infusion, normal saline solution , 1000 cc <1% 1,948 $3K
94729 <1% 41 $3K
96375 Therapeutic injection; each additional sequential IV push <1% 2,656 $3K
11721 <1% 126 $3K
94726 <1% 49 $3K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,331 $3K
83540 <1% 426 $2K
87086 Culture, bacterial; quantitative colony count, urine <1% 1,624 $2K
82947 <1% 1,551 $2K
85730 <1% 3,164 $2K
11719 <1% 165 $2K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 1,602 $2K
85379 <1% 1,506 $2K
84703 <1% 1,370 $2K
82077 <1% 866 $2K
82948 <1% 2,033 $2K
96367 <1% 84 $2K
82248 <1% 2,019 $2K
83690 <1% 2,603 $1K
90715 <1% 104 $1K
82803 <1% 1,172 $1K
82565 <1% 147 $1K
82140 <1% 418 $1K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 726 $1K
81003 <1% 1,559 $1K
96376 <1% 715 $1K
73560 <1% 118 $1K
80143 <1% 498 $1K
76536 <1% 12 $962.38
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 987 $877.25
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 2,319 $851.25
80179 <1% 473 $851.00
86140 <1% 123 $746.70
97162 <1% 16 $712.11
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 1,564 $671.62
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 89 $628.03
82550 <1% 384 $610.37
82570 <1% 92 $589.60
73502 <1% 36 $532.11
87186 <1% 815 $502.06
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 44 $481.89
94761 <1% 786 $478.28
83525 <1% 84 $460.38
90656 <1% 56 $434.07
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 1,020 $432.72
73590 <1% 18 $411.36
82150 <1% 837 $401.04
87420 <1% 216 $400.89
87081 <1% 115 $344.93
82962 <1% 822 $323.69
74018 <1% 19 $312.29
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 780 $272.77
94760 <1% 437 $261.09
84100 <1% 225 $239.04
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 215 $229.85
85652 <1% 92 $217.94
84439 <1% 15 $216.93
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 14 $199.64
84466 <1% 56 $178.35
J1170 Injection, hydromorphone, up to 4 mg <1% 423 $164.56
73110 <1% 12 $133.08
87280 <1% 78 $129.86
81025 <1% 169 $125.86
82728 <1% 57 $122.39
87400 <1% 125 $116.06
90460 Immunization administration through 18 years of age via any route, first or only component <1% 26 $113.24
87077 <1% 43 $87.04
J0780 Injection, prochlorperazine, up to 10 mg <1% 389 $83.34
80320 <1% 13 $82.52
84156 <1% 15 $71.70
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg <1% 128 $71.28
74022 <1% 41 $69.44
87581 <1% 14 $67.10
J1030 Injection, methylprednisolone acetate, 40 mg <1% 52 $65.06
36600 <1% 128 $64.73
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 129 $55.92
J2543 Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) <1% 38 $55.26
82746 <1% 48 $54.25
87430 <1% 59 $49.74
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 209 $47.40
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 336 $44.00
87486 <1% 14 $33.55
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 14 $33.55
51702 <1% 14 $29.20
90732 <1% 13 $27.30
J2060 Injection, lorazepam, 2 mg <1% 132 $19.87
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 266 $16.77
C9113 Injection, pantoprazole sodium, per vial <1% 19 $16.51
J7050 Infusion, normal saline solution, 250 cc <1% 167 $13.71
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 186 $12.42
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 615 $11.70
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 53 $11.56
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 14 $8.40
J2270 Injection, morphine sulfate, up to 10 mg <1% 24 $7.75
84132 <1% 39 $6.35
J3010 Injection, fentanyl citrate, 0.1 mg <1% 33 $2.49
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 14 $2.40
J7060 5% dextrose/water (500 ml = 1 unit) <1% 67 $2.17
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 14 $0.91
64494 0% 14 $0.00
J0456 Injection, azithromycin, 500 mg 0% 14 $0.00
A9270 Non-covered item or service 0% 1,027 $0.00
G0008 Administration of influenza virus vaccine 0% 313 $0.00
J1010 Injection, methylprednisolone acetate, 1 mg 0% 79 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 0% 28 $0.00
J2704 Injection, propofol, 10 mg 0% 17 $0.00
J1940 Injection, furosemide, up to 20 mg 0% 29 $0.00
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program 0% 554 $0.00
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 0% 42 $0.00
99218 0% 47 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCRAFT, JEFFREY (VICE PRESIDENT FOR SYSTEM FINANCE)